Treatment-by-single nucleotide polymorphism interaction test
| MAVERICC | TRIBE | |||||||||||
| Hazard ratio on PFS | Hazard ratio on OS | Hazard ratio on PFS | Hazard ratio on OS | |||||||||
| FOLFOX+ BEV | FOLFIRI+ BEV | Interaction p value | FOLFOX+ BEV | FOLFIRI+ BEV | Interaction p value | FOLFOXIRI+ BEV | FOLFIRI+ BEV | Interaction p value | FOLFIRI+ BEV | FOLFIRI+ BEV | Interaction p value | |
| CALR rs1049481 | ||||||||||||
| T/T | 1 | 1 | 0.87 | 1 | 1 | 0.98 | 1 | 1 | 0.11 | 1 | 1 | 0.42 |
| Any G | 0.85 (0.54–1.36) | 0.91 (0.54–1.51) | 1.03 (0.60–1.76) | 0.92 (0.47–1.78) | 0.69 (0.39–1.21) | 1.14 (0.81–1.62) | 0.74 (0.45–1.24) | 0.97 (0.69–1.36) | ||||
| CALR rs1010222 | ||||||||||||
| G/G | 1 | 1 | 0.41 | 1 | 1 | 0.41 | 1 | 1 | 0.34 | 1 | 1 | 0.57 |
| Any A | 0.67 (0.42–1.07) | 0.96 (0.58–1.60) | 0.78 (0.46–1.35) | 0.97 (0.50–1.89) | 0.87 (0.52–1.46) | 1.11 (0.79–1.56) | 0.79 (0.49–1.29) | 0.96 (1.69–1.33) | ||||
| HMGB1 rs1045411 | ||||||||||||
| C/C | 1 | 1 | 0.35 | 1 | 1 | 0.58 | 1 | 1 | 0.07 | 1 | 1 | 0.50 |
| Any T | 1.43 (0.85–2.41) | 1.09 (0.63–1.89) | 1.46 (0.79–2.69) | 1.20 (0.58–2.48) | 1.93 (1.06–3.53) | 1.11 (0.74–1.65) | 1.03 (0.59–1.80) | 0.95 (0.65–1.38) | ||||
| HMGB1 rs1412125 | ||||||||||||
| T/T | 1 | 1 | 0.87 | 1 | 1 | 0.51 | 1 | 1 | 0.30 | 1 | 1 | 0.11 |
| Any C | 0.74 (0.43–1.28) | 0.78 (0.45–1.35) | 0.80 (0.43–1.48) | 1.06 (0.52–2.16) | 1.22 (0.64–2.30) | 0.98 (0.69–1.40) | 1.14 (0.64–2.01) | 0.83 (0.58–1.17) | ||||
| HMGB1 rs1360485 | ||||||||||||
| T/T | 1 | 1 | 0.28 | 1 | 1 | 0.73 | 1 | 1 | 0.04 | 1 | 1 | 0.42 |
| Any C | 1.45 (0.89–2.38) | 1.03 (0.62–1.69) | 1.38 (0.78–2.43) | 1.19 (0.62–2.25) | 1.70 (0.95–3.06) | 1.06 (0.74–1.50) | 0.93 (0.54–1.60) | 0.98 (0.70–1.37) | ||||
| ANXA1 rs1050305 | ||||||||||||
| A/A | 1 | 1 | 0.82 | 1 | 1 | 0.15 | 1 | 1 | 0.16 | 1 | 1 | 0.002 |
| Any G | 1.29 (0.66–2.51) | 1.07 (0.54–2.11) | 1.96 (0.93–4.12) | 0.81 (0.33–1.98) | 1.62 (0.83–3.16) | 1.09 (0.68–1.74) | 2.00 (1.07–3.72) | 0.67 (0.42–1.09) | ||||
| LRP1 rs1799986 | ||||||||||||
| C/C | 1 | 1 | 0.66 | 1 | 1 | 0.23 | 1 | 1 | 0.03 | 1 | 1 | 0.55 |
| Any T | 1.18 (0.71–1.94) | 0.93 (0.52–1.66) | 1.55 (0.87–2.74) | 0.71 (0.33–1.53) | 2.71 (1.37–5.37) | 0.90 (0.60–1.34) | 1.30 (0.70–2.40) | 1.10 (0.73–1.66) | ||||
| LRP1 rs11172113 | ||||||||||||
| T/T | 1 | 1 | 0.31 | 1 | 1 | 0.73 | 1 | 1 | 0.004 | 1 | 1 | 0.004 |
| Any C | 1.05 (0.63–1.74) | 1.22 (0.72–2.06) | 0.97 (0.55–1.69) | 0.66 (0.34–1.26) | 0.55 (0.31–0.98) | 1.35 (0.96–1.89) | 0.58 (0.34–0.96) | 1.20 (0.87–1.67) | ||||
| P2R×7 rs208294 | ||||||||||||
| C/C | 1 | 1 | 0.33 | 1 | 1 | 0.046 | 1 | 1 | 0.62 | 1 | 1 | 0.02 |
| Any T | 0.93 (0.55–1.58) | 1.26 (0.72–2.22) | 0.62 (0.33–1.16) | 1.84 (0.84–4.06) | 0.92 (0.54–1.58) | 1.02 (0.71–1.47) | 0.54 (0.33–0.89) | 0.92 (0.64–1.32) | ||||
| P2R×7 rs1718119 | ||||||||||||
| G/G | 1 | 1 | 0.66 | 1 | 1 | 0.03 | 1 | 1 | 0.85 | 1 | 1 | 0.77 |
| Any A | 1.02 (0.62–1.70) | 1.26 (0.74–2.14) | 0.97 (0.53–1.78) | 2.57 (1.16–5.67) | 0.77 (0.45–1.31) | 0.87 (0.62–1.21) | 0.69 (0.42–1.15) | 0.83 (0.60–1.15) | ||||
Significant values are indicated in bold characters. Each HR is presented with a point estimate and a 95% CI (in parentheses) calculated in the multivariate analyzes.
BEV, bevacizumab; OS, overall survival; PFS, progression-free survival.